Actively Recruiting
Study of Early Restart Versus Usual Care of Renin-Angiotensin System Inhibitors After Acute Kidney Injury in Hospitalized Adults
Led by University of California, San Francisco · Updated on 2026-09-08
60
Participants Needed
1
Research Sites
N/A
Total Duration
AI-Summary
What This Trial Is About
This research aims to evaluate if restarting renin-angiotensin system inhibitor RASi medications early after acute kidney injury AKI is feasible and well-tolerated in hospitalized patients. It compares an early RASi restart strategy to usual care among patients who had their RASi stopped during AKI. The study is a pilot trial designed to provide data for a larger future study and is sponsored by the University of California, San Francisco. The trial has two groups one where RASi medications are restarted early based on specific kidney function and blood pressure criteria, and another receiving usual care where RASi restart decisions are left to the participants healthcare providers. Participants in the early restart group resume RASi when serum creatinine decreases by at least 0.3 mgdL from peak, potassium levels are 5 mEqL or less, estimated kidney function meets a threshold, and blood pressure is stable. If discharge occurs before these criteria are met, outpatient providers manage RASi restart. Participants will be monitored through lab tests 1 to 2 weeks after hospital discharge if not done routinely, and will answer follow-up questions at 90 days. Researchers will assess feasibility by measuring RASi use timing up to 90 days, and evaluate tolerability through follow-up completion, kidney function tests, and proteinuria assessments. The total study duration extends up to 90 days from enrollment or hospital discharge.
CONDITIONS
Brief Title
A Prompt REstart Study of Renin-Angiotensin System Inhibitors After Acute Kidney Injury
Research Team
Y
Yuenting D Kwong, MD MAS
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here